Latest Regulatory News

Finder Energy has acquired the Petrojarl I FPSO from Amplus Energy for US$15 million, aiming to fast-track its KTJ oil development project with a targeted final investment decision by mid-2026 and first oil by the end of 2027. This move is supported by a two-tranche institutional placement raising A$25 million at a 21.3% discount.

Vulcan Energy Resources has locked in full financing for its Phase One Lionheart project, marking a pivotal step toward producing carbon-neutral lithium hydroxide in Germany by 2028. The €2.2 billion package combines debt, equity, and government grants, underpinning robust project economics and strategic partnerships.

OncoSil Medical’s interim OSPREY registry data reveals promising survival improvements for patients with unresectable locally advanced pancreatic cancer treated with OncoSil™ plus chemotherapy. The findings suggest a meaningful step forward in a field with limited effective options.

LTR Pharma has secured ethics approval for its Phase II SPONTAN clinical trial, focusing on pharmacokinetics and dosing in men aged 65 and older. Recruitment begins early 2026 with initial results expected mid-year.

Chariot Resources has amended its acquisition agreement for a Nigerian lithium portfolio, securing financing and extending the closing deadline to May 2026. The move reinforces exclusivity protections and paves the way for a smoother transaction completion.

Nexsen Limited has appointed internationally acclaimed surgeon-scientist Professor Shekhar Kumta to its board, aiming to fast-track clinical validation and regulatory approval for its rapid diagnostic platforms ahead of a planned 2026 market entry.

White Cliff Minerals has identified multiple high-priority copper targets along the 10km Teshierpi Fault Zone at its Rae Copper Project in Nunavut, Canada, following a comprehensive 2025 airborne electromagnetic survey. The findings extend known mineralisation at Danvers and set the stage for follow-up drilling in early 2026.

Prairie Lithium has completed critical groundwork at its Canadian lithium brine project, setting the stage for construction and commercial operations in 2026 amid rising lithium prices.

QuickFee Limited has completed a $28.5 million capital return following the sale of its US Pay Now and Connect businesses, while updating its dividend policy to target regular shareholder cash distributions starting in FY26.

Transurban Group has announced a 34-cent unfranked dividend per stapled security for the six months ending December 2025, alongside a Dividend Reinvestment Plan with no discount.

Invion Limited has expanded its global rights to the Photosoft™ technology, gaining exclusive perpetual licenses across a broad range of human and animal diseases, including cancers and infectious diseases. This milestone-based deal positions Invion to accelerate clinical development and commercialisation worldwide.

Island Pharmaceuticals has secured over $1 million through option exercises by directors and major shareholders, bolstering its cash reserves to advance the clinical and regulatory development of its broad-spectrum antiviral, Galidesivir.